CY2019002I2 - Εγκαρσια συνδεδεμενα πολυμερη ανταλλαγης κατιοντος, συνθεσεις και χρηση στη θεραπεια υπερκαλιαιμιας - Google Patents

Εγκαρσια συνδεδεμενα πολυμερη ανταλλαγης κατιοντος, συνθεσεις και χρηση στη θεραπεια υπερκαλιαιμιας

Info

Publication number
CY2019002I2
CY2019002I2 CY2019002C CY2019002C CY2019002I2 CY 2019002 I2 CY2019002 I2 CY 2019002I2 CY 2019002 C CY2019002 C CY 2019002C CY 2019002 C CY2019002 C CY 2019002C CY 2019002 I2 CY2019002 I2 CY 2019002I2
Authority
CY
Cyprus
Prior art keywords
hyperkalasemia
compositions
treatment
cross
cation exchange
Prior art date
Application number
CY2019002C
Other languages
English (en)
Other versions
CY2019002I1 (el
Original Assignee
Vifor (International) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41707686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2019002(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vifor (International) Ltd. filed Critical Vifor (International) Ltd.
Publication of CY2019002I1 publication Critical patent/CY2019002I1/el
Publication of CY2019002I2 publication Critical patent/CY2019002I2/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/16—Organic material
    • B01J39/18—Macromolecular compounds
    • B01J39/20—Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/22—Esters containing halogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F212/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
    • C08F212/34—Monomers containing two or more unsaturated aliphatic radicals
    • C08F212/36—Divinylbenzene

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
CY2019002C 2008-08-22 2019-01-09 Εγκαρσια συνδεδεμενα πολυμερη ανταλλαγης κατιοντος, συνθεσεις και χρηση στη θεραπεια υπερκαλιαιμιας CY2019002I2 (el)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US9111008P 2008-08-22 2008-08-22
US9112508P 2008-08-22 2008-08-22
US9109708P 2008-08-22 2008-08-22
US16589409P 2009-04-01 2009-04-01
US16589909P 2009-04-01 2009-04-01
US16590509P 2009-04-02 2009-04-02
PCT/US2009/054706 WO2010022383A2 (en) 2008-08-22 2009-08-22 Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
EP09748557.7A EP2365988B2 (en) 2008-08-22 2009-08-22 Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia

Publications (2)

Publication Number Publication Date
CY2019002I1 CY2019002I1 (el) 2020-05-29
CY2019002I2 true CY2019002I2 (el) 2020-05-29

Family

ID=41707686

Family Applications (3)

Application Number Title Priority Date Filing Date
CY2018002C CY2018002I1 (el) 2008-08-22 2018-01-15 Εγκαρσια συνδεδεμενα πολυμερη εναλλαγης κατιοντος, συνθεσεις και χρηση στη θεραπεια υπερκαλιαιμιας
CY20181101268T CY1120930T1 (el) 2008-08-22 2018-11-29 Εγκαρσια συνδεδεμενα πολυμερη ανταλλαγης κατιοντος, συνθεσεις και χρηση στη θεραπεια υπερκαλιαιμιας
CY2019002C CY2019002I2 (el) 2008-08-22 2019-01-09 Εγκαρσια συνδεδεμενα πολυμερη ανταλλαγης κατιοντος, συνθεσεις και χρηση στη θεραπεια υπερκαλιαιμιας

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY2018002C CY2018002I1 (el) 2008-08-22 2018-01-15 Εγκαρσια συνδεδεμενα πολυμερη εναλλαγης κατιοντος, συνθεσεις και χρηση στη θεραπεια υπερκαλιαιμιας
CY20181101268T CY1120930T1 (el) 2008-08-22 2018-11-29 Εγκαρσια συνδεδεμενα πολυμερη ανταλλαγης κατιοντος, συνθεσεις και χρηση στη θεραπεια υπερκαλιαιμιας

Country Status (27)

Country Link
US (4) US20110236340A1 (el)
EP (4) EP2957286B1 (el)
JP (7) JP5756403B2 (el)
KR (5) KR101825113B1 (el)
CN (2) CN102202670B (el)
AU (1) AU2009282721B2 (el)
BR (1) BRPI0917853C1 (el)
CA (1) CA2735058C (el)
CY (3) CY2018002I1 (el)
DE (1) DE112009002063T5 (el)
DK (3) DK2365988T4 (el)
ES (3) ES2545887T5 (el)
FI (1) FI3431094T3 (el)
GB (4) GB2495427B (el)
HK (1) HK1184675A1 (el)
HR (3) HRP20230091T1 (el)
HU (3) HUE061320T2 (el)
LT (4) LT2957286T (el)
LU (1) LUC00094I2 (el)
MX (2) MX364398B (el)
NL (1) NL300962I2 (el)
NO (2) NO2018004I1 (el)
PL (3) PL2957286T3 (el)
PT (3) PT2365988E (el)
SI (2) SI2957286T1 (el)
SM (1) SMT201500207T1 (el)
WO (1) WO2010022383A2 (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8574716B2 (en) * 2006-01-23 2013-11-05 Hitachi Chemical Co., Ltd. Ionic polymer devices and methods of fabricating the same
WO2010022380A2 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
PT2365988E (pt) 2008-08-22 2015-10-22 Relypsa Inc Polímeros de permuta iónica reticulados, composições e uso no tratamento da hipercalemia
KR101839038B1 (ko) 2010-03-20 2018-03-16 리립사, 인크. 폴리플루오로아크릴레이트 입자를 제조하기 위한 연속식 방법
CN109106725A (zh) 2011-02-11 2019-01-01 Zs制药公司 用于治疗高钾血症的微孔性的硅酸锆
ES2758708T3 (es) 2011-06-27 2020-05-06 Relypsa Inc Fluoración de ésteres de acrilato y derivados
ES2895909T3 (es) * 2011-06-27 2022-02-23 Vifor Pharma Tech Ltd Procedimiento para la conversión de un éster polimérico a un ácido polimérico
AU2013292350B9 (en) * 2012-07-19 2018-08-23 Vifor Pharma Technology Ltd. Compositions comprising crosslinked cation-binding polymers
JP6115973B2 (ja) * 2012-08-09 2017-04-19 パセオン オーストリア ゲーエムベーハー ウント ツェーオー カーゲー ポリマー材料の乾燥方法
JP6475624B2 (ja) * 2012-10-08 2019-02-27 レリプサ， インコーポレイテッド 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
US10695365B2 (en) 2012-10-22 2020-06-30 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
JP6280636B2 (ja) 2013-04-05 2018-02-14 ズィーエス・ファーマ，インコーポレーテッド カリウムの低減と慢性腎臓病及び／または慢性心臓病の治療のための微多孔性ケイ酸ジルコニウム及び利尿剤
NZ732542A (en) * 2014-12-23 2023-02-24 Ardelyx Inc Compositions and methods for treating hyperkalemia
US11028443B2 (en) 2015-08-31 2021-06-08 Showa Denko Materials Co., Ltd. Molecular methods for assessing urothelial disease
US9592253B1 (en) 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
ITUB20159278A1 (it) 2015-12-23 2017-06-23 Rjw Pharma Llc Procedimento per la sintesi di patiromer
WO2019220450A1 (en) 2018-05-16 2019-11-21 Solara Active Pharma Sciences Limited Process for preparation of patiromer
CA3132563A1 (en) * 2019-03-13 2020-09-17 Astrazeneca Ab Potassium-binding agents for use in hemodialysis patients
WO2021097012A1 (en) * 2019-11-14 2021-05-20 Relypsa, Inc. One step synthesis for alkyl 2-fluoroacrylates
CN116323717A (zh) * 2021-09-13 2023-06-23 中美华世通生物医药科技(武汉)股份有限公司 治疗高钾血症的聚合物药物及其制备方法
US20240139234A1 (en) * 2021-11-17 2024-05-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Pharmaceutical polymer for treating hyperkalemia and preparation method thereof
CN114369729B (zh) * 2021-12-28 2023-11-03 江苏容汇通用锂业股份有限公司 一种利用锂矿渣进行浸出液除钾的工艺
CN114394918B (zh) * 2022-01-19 2023-10-20 罗长青 一种2-[[三(羟甲基)甲基]氨基]乙磺酸的制备方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611730A (en) * 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
US2909462A (en) * 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3499960A (en) * 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
NL137053C (el) † 1967-01-30
FR2171934B1 (el) * 1972-02-16 1974-09-13 Rhone Poulenc Sa
US3974272A (en) * 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4143130A (en) * 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4470975A (en) * 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4380590A (en) * 1978-09-19 1983-04-19 Rohm And Haas Company Emulsion copolymer cation exchange resins
DE2846187A1 (de) † 1978-10-24 1980-05-08 Bayer Ag Kunstharze auf basis vernetzter mischpolymerisate aus mono- und polyvinylverbindungen
JPS6090243A (ja) * 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
US4747881A (en) * 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US5186937A (en) * 1985-06-07 1993-02-16 A.E.C. Societe De Chimie Organique Et Biologique Composition for feeding ruminants
IT1190349B (it) * 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
JPS63218713A (ja) * 1987-02-17 1988-09-12 Daikin Ind Ltd α−フルオロアクリル酸系重合体ならびに用途
US4837015A (en) * 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
GB8817015D0 (en) * 1988-07-16 1988-08-17 Reckitt & Colmann Prod Ltd Method of treatment
GB8829088D0 (en) † 1988-12-13 1989-01-25 Smith Kline French Lab Compounds
US5236701A (en) * 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
DE3928990A1 (de) 1989-09-01 1991-03-07 Bayer Ag Verfahren zur herstellung von (alpha)-fluoroacrylsaeurederivaten
US5112993A (en) 1989-11-14 1992-05-12 E. I. Du Pont De Nemours And Company Process for the preparation of difluoromaleic anhydride
US5091175A (en) * 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
ES2070307T3 (es) * 1990-07-04 1995-06-01 Marcin Krotkiewski Una preparacion para el tratamiento de la hipertension.
US5162110A (en) * 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
US5281631A (en) * 1991-12-20 1994-01-25 Arch Development Corp. Phosphonic acid based ion exchange resins
DE69306844T2 (de) † 1992-04-10 1997-07-10 Mitsubishi Chem Corp Verfahren zur Herstellung von kugelförmigen vernetzten Acrylnitril-Copolymerisaten
PL307527A1 (en) * 1992-08-20 1995-05-29 Du Pont Crosslinked polymeric ammonium salts
US5487888A (en) * 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5618530A (en) * 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
ES2112516T3 (es) * 1993-11-25 1998-04-01 Salternate B V Particulas para fijar cationes monovalentes y su uso.
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
US6280717B1 (en) * 1998-07-31 2001-08-28 Nikken Chemicals Co., Ltd. Cation exchange resin preparation
US6294163B1 (en) * 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
US6558665B1 (en) * 1999-05-18 2003-05-06 Arch Development Corporation Encapsulating particles with coatings that conform to size and shape of the particles
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
US6733780B1 (en) * 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
DE19951116A1 (de) 1999-10-23 2001-04-26 Bosch Gmbh Robert Relais, insbesondere für eine Startvorrichtung
DE19962935A1 (de) † 1999-12-24 2001-06-28 Bayer Ag Verfahren zur Herstellung von vernetzten Ionenaustauschern auf Basis von ungesättigten, aliphatischen Nitrilen
AU780873B2 (en) * 2000-01-14 2005-04-21 Otsuka Pharmaceutical Factory, Inc. Inhibitors against sodium ion absorption, and preventive or therapeutic agents and foods containing the same
US6994827B2 (en) 2000-06-03 2006-02-07 Symyx Technologies, Inc. Parallel semicontinuous or continuous reactors
ATE407689T1 (de) * 2000-08-01 2008-09-15 Oryza Oil & Fat Chem Nachtkerzensamenextrakte als inhibitoren der zuckerabsorption und deren herstellungsprozess
US6908609B2 (en) * 2000-11-20 2005-06-21 Dow Global Technologies Inc. In vivo use of water absorbent polymers
US7033639B2 (en) * 2001-05-16 2006-04-25 Rohm And Haas Company Polyaniline coating composition
US6881484B2 (en) * 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
CA2516457C (en) * 2003-02-25 2011-12-06 Finnfeeds Finland Oy A simulated moving bed system and process
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
US7429394B2 (en) * 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
EP1732516B1 (en) * 2004-03-30 2009-12-30 Relypsa, Inc. Ion binding compositions
US8282960B2 (en) * 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7556799B2 (en) † 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
US7854924B2 (en) * 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US8192758B2 (en) * 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
WO2007038801A2 (en) † 2005-09-30 2007-04-05 Ilypsa, Inc. Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
BRPI0616604A2 (pt) * 2005-09-30 2012-12-25 Ilypsa Inc mÉtodo para remover e composiÇço para seletivamente remover Íon de potÁssio do trato gastrintestinal de um mamÍfero, mÉtodo para seletivamente remover Íon de potÁssio de um meio-ambiente, composiÇço farmacÊutica, partÍcula de nécleo-envoltàrio, e, usos de uma partÍcula de nécleo-envoltàrio e de uma composiÇço farmacÊutica
DE112006002617T5 (de) * 2005-09-30 2008-08-28 Ilypsa Inc., Santa Clara Verfahren zur Herstellung von Core-Shell-Kompositen bzw. Kern-Hüllen-Kompositen mit vernetzten Hüllen und daraus entstehende Core-Shell-Komposite
EP2187979B1 (en) * 2007-08-29 2014-09-24 Sorbent Therapeutics, Inc. Absorbent polymeric compositions with varying counterion content and their methods of preparation and use
WO2010022381A1 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US20100111892A1 (en) * 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
WO2010022380A2 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
PT2365988E (pt) † 2008-08-22 2015-10-22 Relypsa Inc Polímeros de permuta iónica reticulados, composições e uso no tratamento da hipercalemia

Also Published As

Publication number Publication date
HUS1900003I1 (hu) 2019-02-28
ES2545887T3 (es) 2015-09-16
FI3431094T3 (fi) 2023-03-20
ES2545887T5 (es) 2020-02-17
CN102202670A (zh) 2011-09-28
PL3431094T3 (pl) 2023-04-24
BRPI0917853C1 (pt) 2021-05-25
LTC2957286I2 (lt) 2019-11-25
HUE061320T2 (hu) 2023-06-28
EP2365988B1 (en) 2015-07-22
GB201222752D0 (en) 2013-01-30
MX364398B (es) 2019-04-24
AU2009282721A1 (en) 2010-02-25
HUE025934T2 (en) 2016-05-30
GB2475657A (en) 2011-05-25
GB2495426A (en) 2013-04-10
EP2365988B2 (en) 2019-07-03
LT2957286T (lt) 2018-12-10
WO2010022383A2 (en) 2010-02-25
GB201222749D0 (en) 2013-01-30
HRP20230091T1 (hr) 2023-03-17
US20110236340A1 (en) 2011-09-29
HK1184675A1 (en) 2014-01-30
BRPI0917853B1 (pt) 2020-04-07
MX2011001893A (es) 2011-09-27
CN103919792B (zh) 2018-03-09
CY2018002I1 (el) 2019-07-10
LTPA2018016I1 (lt) 2019-01-10
GB201104561D0 (en) 2011-05-04
WO2010022383A3 (en) 2010-09-23
CY2019002I1 (el) 2020-05-29
LUC00094I1 (el) 2018-12-19
ES2939021T3 (es) 2023-04-18
DK2365988T3 (en) 2015-10-26
HRP20150955T1 (hr) 2015-10-09
EP2957286B1 (en) 2018-11-21
EP2957286A1 (en) 2015-12-23
JP2012500806A (ja) 2012-01-12
CN103919792A (zh) 2014-07-16
PT3431094T (pt) 2023-03-03
CN102202670B (zh) 2014-04-30
KR101928973B1 (ko) 2018-12-13
NO2018041I1 (el) 2018-12-14
SI3431094T1 (sl) 2023-04-28
CA2735058A1 (en) 2010-02-25
NL300962I2 (nl) 2020-06-02
PL2957286T3 (pl) 2019-03-29
PL2365988T5 (pl) 2019-11-29
DK3431094T3 (da) 2023-02-20
EP3431094B1 (en) 2022-12-07
KR20200128600A (ko) 2020-11-13
KR102178208B1 (ko) 2020-11-12
LT3431094T (lt) 2023-02-27
EP3431094A1 (en) 2019-01-23
CA2735058C (en) 2021-01-26
LUC00094I2 (el) 2020-01-23
EP4201408A1 (en) 2023-06-28
NO2018004I1 (no) 2018-01-17
JP2017218454A (ja) 2017-12-14
JP2019065030A (ja) 2019-04-25
BRPI0917853B8 (pt) 2020-04-22
LTPA2018004I1 (lt) 2018-02-12
JP5756403B2 (ja) 2015-07-29
KR20180014845A (ko) 2018-02-09
PT2365988E (pt) 2015-10-22
JP2020172537A (ja) 2020-10-22
DK2365988T4 (da) 2019-10-07
SI2957286T1 (sl) 2018-12-31
HRP20181961T1 (hr) 2019-02-08
EP2365988A2 (en) 2011-09-21
GB201222750D0 (en) 2013-01-30
KR20180133561A (ko) 2018-12-14
GB2495428A (en) 2013-04-10
KR101825113B1 (ko) 2018-02-02
CY1120930T1 (el) 2020-05-29
KR102300471B1 (ko) 2021-09-30
JP5883471B2 (ja) 2016-03-15
BRPI0917853A2 (pt) 2015-11-24
DE112009002063T5 (de) 2012-01-12
NL300962I1 (nl) 2018-12-28
DK2957286T3 (en) 2018-12-17
US20200289550A1 (en) 2020-09-17
JP2014144977A (ja) 2014-08-14
KR20110063647A (ko) 2011-06-13
AU2009282721B2 (en) 2015-10-29
JP6633583B2 (ja) 2020-01-22
JP6890116B2 (ja) 2021-06-18
ES2699494T3 (es) 2019-02-11
US20170165292A1 (en) 2017-06-15
US20220000906A1 (en) 2022-01-06
GB2495427A (en) 2013-04-10
GB2475657B (en) 2013-05-29
PL2365988T3 (pl) 2015-12-31
GB2495427B (en) 2013-08-07
JP2014144978A (ja) 2014-08-14
KR20200029614A (ko) 2020-03-18
PT2957286T (pt) 2018-11-30
JP6232468B2 (ja) 2017-11-15
JP2016145256A (ja) 2016-08-12
SMT201500207T1 (it) 2015-10-30
KR102150184B1 (ko) 2020-08-31

Similar Documents

Publication Publication Date Title
CY2019002I2 (el) Εγκαρσια συνδεδεμενα πολυμερη ανταλλαγης κατιοντος, συνθεσεις και χρηση στη θεραπεια υπερκαλιαιμιας
LTPA2020006I1 (lt) GDF gaudyklės, skirtos naudoti anemijos gydymui
BRPI0913574A2 (pt) composição de tratamento de acne compreendendo nanoprata e usos
CO6791606A2 (es) Composiciones y métodos para el tratamiento en aplicaciones clínicas de amplio espectro, no diferenciadas o combinadas
BRPI0819361A2 (pt) Composição de tratamento de cabelos e agente de tratamento
BRPI0807908A2 (pt) Melhoramentos em composições medicinais.
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BRPI0911612A2 (pt) composições e métodos para o tratamento da esclerose múltipla.
BRPI0809802A2 (pt) "composição granular para tratamento de água, tablete para tratamento de água, composição para tratamento de água e método de tratamento de água para recreação"
DK2004183T3 (da) Mazindol-kombination i behandlingen af opmærksomhedsunderskud/hyperaktivitet
BRPI0908139A2 (pt) Agente de formação de espuma para uma composição de dentifrício, composição de centifrício, e, método para tratamento e/ou alívio de xerostomia
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
DK3156057T3 (da) Delmopinol-belagt dyretyggeartikel til anvendelse til forebyggelsen eller behandlingen af halitosis
BRPI0810762A2 (pt) Composição para tratamento da água
BRPI0821100A2 (pt) composições e métodos para o tratamento de câncer de bexiga
FR2921558B1 (fr) Composition antimicrobienne utilisable en cosmetique et en dermatologie.
HUS1800004I1 (hu) Térhálósított kationcserélõ polimerek, az ezeket tartalmazó készítmények és alkalmazásuk hiperkalémia kezelésére
BR112012025829A2 (pt) ''composição de tratamento, composição líquido e utilização''
GB2466110B (en) Antibacterial formulation for use in the treatment of acne
SI2365988T1 (sl) Zamreženi polimeri za kationsko izmenjavo, sestave in uporaba pri zdravljenju hiperkaliemije
TH0801001896A (th) การใช้ 4-ไซโคลโพรพิลเมธอกซิ-n-(3,5-ไดคลอโร-1-ออกซิโด-ไพริดิน-4-อิล)-5-(เมธอกซิ)ไพริดีน-2-คาร์บอกซามีด ในการรักษาการบาดเจ็บไขสันหลัง